Royalty Pharma Financials - Benzinga

Royalty Pharma PLC

RPRXNASDAQ

Trade with Public

Trade with Public

$58.21

-0.08-0.14%

al cierre: Sep 25, 5:00 PM EST

$58.27

0.060.1%

After hour: Sep 25, 4:05 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

Royalty Pharma Financials

Royalty Pharma (RPRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14 per share from the

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.21 by 7.44 percent. This is a 22.64 percent increase over earnings of $1.06 per share from the

Benzinga Newsdesk

Royalty Pharma Q4 Earnings Report: What Investors Need to Know

Benzinga Insights

PRO
Royalty Pharma Q4 Adj. EPS $1.47 Beats $1.33 Estimate, Sales $622.000M Miss $795.915M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.33 by 10.86 percent. This is a 26.72 percent increase over earnings of $1.16 per share from the

Benzinga Newsdesk

Earnings Scheduled For February 11, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved